HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Active:	No
Cancer Type:	Lung Cancer	NCT ID:	NCT04619004
Trial Phases:	Phase II	Protocol IDs:	U31402-A-U201 (primary) NCI-2021-01330 2020-000730-17
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Daiichi Sankyo
NCI Full Details:	http://clinicaltrials.gov/show/NCT04619004

Summary

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in
participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon
19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1
platinum-based chemotherapy-containing regimen.

Objectives

This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive
either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab
deruxtecan (HER3-DXd, U3-1402).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.